Gilead's takeover of Forty Seven should soothe shareholders' worries
Gilean, the biopharma giant, is stocking up on potentially lucrative cancer drugs by snapping up smaller operators.
Five funds to buy into biotech's healthy future
The biotech sector has struggled over the past year, but it remains a solid long-term investment. Here are five good ways to buy in.
The best way to play the biotech boom
Syncona is an unusual investment trust that invests in promising privately held biotech companies. It should be a core holding in any portfolio, says …
How stem cells are changing the face of medicine
We have only just started getting to grips with the vast life-saving potential of stem cells, the basic building blocks of the body. Dr Mike Tubbs exp…
How to profit from the age of bespoke medicine
Doctors have traditionally approached diseases with a one-size-fits-all model. But advances in genetics and artificial intelligence are making medical…
The drugs don’t work: stopping the spread of the superbugs
Antibiotic resistance could turn medical inconveniences into death sentences and become a bigger killer than cancer. Governments and pharmaceutical co…